Navigation Links
Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options

- Promotes Commercial Products at Major Cardiology Conferences -

- Convenes Opinion Leaders to Assist Product Development Efforts -

- Achieves Efficiencies and Conserves Cash by Consolidating R&D

Operations -

VANCOUVER, Nov. 3 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), a new specialty vascular device company, today reported on its commercial and product development progress, the consolidation and streamlining of its R&D operations, including the appointment of a noted interventional cardiologist as Medical Director, and the issuance of options.

Commercial and Development Progress

Neovasc recently showcased its commercially available products, including its innovative Metricath(R) intravascular measurement system and its Matrix(BP)(TM) biologic vascular patch for carotid procedures at several major cardiovascular medical conferences including New Cardiovascular Horizons (NCVH), Vascular Interventional Advances (VIVA), TransCatheter Therapeutics (TCT) and the Canadian Cardiovascular Congress (CCC). A number of key opinion leaders conducted scientific talks and seminars in support of Neovasc's products at these conferences and leading interventional cardiologists and vascular surgeons also participated in a series of new product development meetings sponsored by Neovasc.

Metricath was featured during NCVH "live case" seminars and in symposiums at VIVA. A breakfast symposium at TCT highlighted the benefits of Metricath with presentations by Dr. Jorge Saucedo, Oklahoma University Medical Center, Dr. Rajesh Dave, Pinnacle Health Heart and Vascular Institute at Harrisburg Hospital, Dr. Raed Aqel, Birmingham VA Medical Center and Dr. David Allie, Cardiovascular Institute of the South/Lafayette. Dr. Allie also presented an abstract for a Metricath study in patients with IPA, a common type of artery disease, in which he concludes that without Metricath, the "primary operator over or underestimated the Metricath-determined vessel more than 50% of cases, and the final treatment frequently changed" (when Metricath measurements were used). Dr. Allie's full study demonstrating the impact of Metricath on assuring optimal treatment is expected to be published in a peer-reviewed journal soon.

The recent product development meetings focused on Neovasc's pipeline of innovative new products including Reducer(TM), a coronary sinus stent for the treatment of chronic refractory angina and the Ostial product line targeting difficult-to-stent lesions occurring at the origin of an artery. Participating opinion leaders provided valuable counsel on development plans, and many expressed enthusiasm about the potential of these product candidates to provide important benefits to physicians and patients. Neovasc intends to provide further details about timelines and clinical strategies as these products proceed toward commercialization.

"We've made great progress in the past few months in advancing our commercially available products and in developing our new product pipeline," said Alexei Marko, CEO and President of Neovasc. "These recent conferences were an excellent opportunity to involve key medical leaders in educating the medical community about the value of our existing products, as well as in obtaining their insights on achieving timely commercialization and optimal positioning for our exciting new products. We look forward to reporting on further progress in our current and new product efforts in the coming months."

Streamlined Operations and Appointment of Medical Director

Following the successful merger of the three former companies that comprise Neovasc (Medical Ventures Corp, Neovasc Medical Ltd, and B-Balloon Ltd.), the company recently took steps to streamline its operations and reduce costs, cutting staff in its Vancouver and Israel operations to realize an overall company headcount reduction of 25%. By focusing on redundancies in the three organizations, management believes that these staff reductions will increase efficiencies without impacting product development operations or timelines. Neovasc also announced the appointment of Prof. Shmuel Banai, an internationally recognized interventional cardiologist and researcher, as Medical Director of Neovasc. Prof. Banai had overall responsibility for the initial development of the company's Reducer and Ostial product candidates and brings more than 25 years of leadership in the interventional cardiology field to Neovasc.

Issuance of Options

On October 31, 2008 the company granted options to its employees, senior officers and directors to acquire a total of 1,157,077 common shares of Neovasc at an exercise price of $1.15 per share expiring on October 31, 2013. Alexei Marko, CEO of Neovasc was granted 290,250 options and CFO Chris Clark was granted 118,750 options. Neovasc directors Paul Geyer, Dr. Jane Hsiao, Steven Rubin and Douglas Janzen were each granted 15,000 options, and directors Dr. William O'Neill and Boaz Lifschitz were each granted 10,000 options. The options will vest 20% immediately and 20% on each anniversary of the grant date for the next four years. The market price at close of previous day was $0.28. The grant of these options is in accordance with the existing stock option plan.

About Neovasc Inc

Neovasc Inc. (formerly Medical Ventures Corp.), is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. Neovasc is comprised of the former Medical Ventures, Neovasc Medical Ltd. and B-Balloon Ltd. The company's current products include Metricath(R) for intravascular measurement and PeriPatch(TM) surgical tissue and staple line reinforcement products. Neovasc has a development pipeline of innovative new products, and provides contract medical device development and manufacturing services. For more information, visit:

Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continues," "estimates," "expects," and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; history of losses and lack of and uncertainty of revenues, ability to obtain required financing, receipt of regulatory approval of product candidates, ability to properly integrate newly acquired businesses, technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with Canadian securities regulators. Although the Company believes that expectations conveyed by the forward-looking statements are reasonable based on the information available to it on the date such statements were made, no assurances can be given as to the future results, approvals or achievements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements except as otherwise required by applicable law.

SOURCE Neovasc Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will ... Friday Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set ... purchase IguanaMed at a discounted price. , IguanaMed’s mission is to outfit ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/27/2015)... ... ... According to an article published November 13th on, much ... revolved around the fact that proper dental care, both at-home and in the dental ... periodontal disease (more commonly referred to as gum disease) and diabetes. According to Dr. ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
Breaking Medicine Technology: